Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
- Posted on August 7, 2025
- By CNBC
- 1 Views
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
